Manufacturers report positive results for ozanimod in trial investigating use in moderate to severe ulcerative colitis

Manufacturers report that in the True North phase III trial, ozanimod, a selective sphingosine 1-phosphate 1 receptor modulator, demonstrated statistically significant rate of induction of clinical remission at week 10, and of maintenance of remission at week 52.


Biospace Inc.